Bioventix Plc Director/PDMR Shareholding

 
TIDMBVXP 
 
Bioventix plc 
 
                        ("Bioventix" or "the Company") 
 
                               Director Dealing 
 
Bioventix plc (BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for applications in 
clinical diagnostics, announces that the Company was notified on 19 November 
2021 that on 15th November 2021 Bruce Hiscock, Chief Financial Officer of the 
Company, purchased a total of 5 ordinary shares of 5 pence each in the Company 
("Ordinary Shares"), at an average price of 3,687 pence per Ordinary Share (the 
"Purchase"). The shares were purchased under a dividend reinvestment plan 
(DRIP). 
 
Following the Purchase, Bruce Hiscock has a beneficial interest in 421 Ordinary 
Shares, representing approximately 0.01 per cent. of the issued share capital 
of the Company. 
 
The notification below, made in accordance with the requirements of the EU 
Market Abuse Regulation, provides further details. 
 
For further information please contact: 
 
Bioventix plc                                     Tel: 01252 728 001 
Peter Harrison           Chief Executive Officer 
 
finnCap Ltd                                       Tel: 020 7220 0500 
Geoff Nash/Simon Hicks   Corporate Finance 
Alice Lane               ECM 
 
This announcement contains inside information for the purposes of Article 7 of 
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law 
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed 
in accordance with the company's obligations under Article 17 of MAR. 
 
Notification and public disclosure of transactions by persons discharging 
managerial responsibilities and persons closely associated with them 
 
1      Details of the person discharging managerial responsibilities / 
       person closely associated 
 
a)     Name                  Bruce Hiscock 
 
2.     Reason for the Notification 
 
a)     Position/status       Chief Financial Officer 
 
b)     Initial notification/ Initial notification 
       Amendment 
 
3.     Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
 
a)     Name                  Bioventix Plc 
 
b)     LEI                   213800225MHX7LZQY108 
 
4.     Details of the transaction(s): section to be repeated for (i) each 
       type of instrument; (ii) each type of transaction; (iii) each date; 
       and (iv) each place where transactions have been conducted 
 
a)     Description of the    Ordinary Shares of 5 pence each 
       Financial instrument, 
       type of instrument 
 
       Identification code   GB00B4QVDF07 
 
b)     Nature of the         Purchase of Ordinary Shares 
       transaction 
 
c)     Price(s) and volume   5 Ordinary Shares of 3,687 pence each 
       (s) 
 
d)     Aggregated            5 Ordinary Shares of 3,687 pence each 
       information: 
 
       ·     Aggregated 
       volume 
 
       ·     Price 
 
e)     Date of the           15 November 2021 
       transaction 
 
f)     Place of the          London Stock Exchange, AIM Market (XLON) 
       transaction 
 
 
 
END

(END) Dow Jones Newswires

November 22, 2021 10:25 ET (15:25 GMT)

Bioventix (AQSE:BVXP.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024